Collaborative Research to Explore New Uses for Existing Radioligands (R21/R33)

The summary for the Collaborative Research to Explore New Uses for Existing Radioligands (R21/R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Collaborative Research to Explore New Uses for Existing Radioligands (R21/R33): -Purpose. The National Institute on Drug Abuse (NIDA), the National Institute on Aging, the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Mental Health (NIMH), through the issuance of this Request for Applications (RFA), seeks to encourage broader uses of established PET/SPECT radioligands by reducing barriers to their wider distribution, and expanding their utility to the study of diseases or organs for which the radioligand has not previously been studied. Applications for this RFA should demonstrate a high degree of innovation and novelty with regard to the new uses for existing radioligands. Although there is no requirement for preliminary data, a clear scientific rationale is essential. Applications for this RFA are expected to propose multi-institutional collaborations between investigators who have the capacity for routine production of a given radioligand for human use, and investigators who lack access to the radioligand but wish to demonstrate the feasibility of an innovative use for the radioligand in a novel patient population. The primary focus of the proposal must be on human studies; animal studies are allowable only if required to obtain regulatory approval for the ligands. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH Phased Innovation Award (R21/R33) grant mechanism. -Funds Available and Anticipated Number of Awards. This RFA has approximately $2.5M set aside to fund meritorious applications that address the goals of this solicitation. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. It is anticipated that between 8 - 10 proposals might be funded under this solicitation.